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Bone remodeling balance is maintained by tight coupling of osteoblast-mediated
bone formation and osteoclast-mediated bone resorption. Thus, agents with the
capacity to regulate osteoblastogenesis and osteoclastogenesis have been investigated
for therapy of bone-related diseases such as osteoporosis. In this study, we
found that wedelolactone, a compound isolated from Ecliptae herba, and a 9-
day incubation fraction of conditioned media obtained from wedelolactone-treated
bone marrow mesenchymal stem cell (BMSC) significantly inhibited tartrate-resistant
acid phosphatase (TRAP) activity in RANKL-stimulated osteoclastic RAW264.7
cells. Addition of the semaphorin 3A (Sema3A) antibody to the conditioned
media partially blocked the medium’s inhibitory effects on the RAW264.7 cells.
In BMSC, mRNA expression of Sema3A increased in the presence of different
wedelolactone concentrations. Blocking Sema3A activity with its antibody reversed
wedelolactone-induced alkaline phosphatase activity in BMSC and concurrently
enhanced wedelolactone-reduced TRAP activity in osteoclastic RAW264.7 cells.
Moreover, in BMSC, wedelolactone enhanced binding of Sema3A with cell-surface
receptors, including neuropilin (NRP)1 and plexinA1. Furthermore, nuclear accumulation
of β-catenin, a transcription factor acting downstream of wedelolactone-induced
Sema3A signaling, was blocked by the Sema3A antibody. In osteoclastic RAW264.7
cells, conditioned media and wedelolactone promoted the formation of plexin A1-NRP1,
but conditioned media also caused the sequestration of the plexin A1-DNAX-activating
protein 12 (DAP12) complex and suppressed the phosphorylation of phospholipase
C (PLC)γ2. These data suggest that wedelolactone promoted osteoblastogenesis
through production of Sema3A, thus inducing the formation of a Sema3A-plexinA1-
Nrp1 complex and β-catenin activation. In osteoclastic RAW264.7 cells, wedelolactone
inhibited osteoclastogenesis through sequestration of the plexinA1-DAP12 complex,
induced the formation of plexinA1-Nrp1 complex, and suppressed PLCγ2 activation.
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INTRODUCTION
Bone homeostasis is maintained by osteoclast-mediated bone
destruction and osteoblast-mediated bone formation, which
are two tightly coupled and controlled processes. An imbalance
between both bone resorption and formation can result in
metabolic bone diseases such as osteoporosis (Martin and
Sims, 2005). Therefore, agents for regulation of the balancing
mechanisms are important for osteoporosis therapy. Many
coupling factors have been identified for regulating the
coordination of osteoblastogenesis and osteoclastogenesis.
For example, differentiation and maturation of osteoclasts
(derived from monocyte/macrophage precursor cells) can
be regulated by osteoblasts, which express key osteoclast
differentiation factors such as receptor activator of nuclear
factor kappa-B ligand (RANKL; Teitelbaum and Ross,
2003). In addition, to counterbalance the activity of these
stimulatory coupling factors, osteoblasts can produce inhibitory
coupling factors, including osteoprotegerin, sclerostin, bone
morphogenetic protein 6 (BMP6), and Wnt10b (Balemans
et al., 2001; Brunkow et al., 2001; Bennett et al., 2005,
2007).
Sema3A is a member of the semaphorin family, a group
of proteins involved in the development of the nervous,
immune systems and bone (Negishi-Koga and Takayanagi,
2012; Worzfeld and Offermanns, 2014). Sema3A, produced
by osteoblasts, has been identified as a potent and direct
inhibitor of osteoclast formation from osteoclast precursor
cells (Gomez et al., 2005; Hayashi et al., 2012). Distinct
from other coupling factors, Sema3A promotes osteoblast
differentiation from bone marrow mesenchymal stem cells
(the precursor of osteoblasts), indicating a dual function
role in which it inhibits osteoclastogenesis and enhances
osteoblastogenesis (Fukuda et al., 2013). The Sema3A signaling
pathway is activated through binding with its cell-surface
receptor composed of an Nrp1 and plexinA1 protein complex,
which functions as a signal-transducing subunit (Gu et al., 2003;
Worzfeld and Offermanns, 2014). This complex induces different
downstream signaling molecules in osteoclasts and osteoblasts,
resulting in different regulatory effects on differentiation.
Therefore, regulation of the Sema3A pathway in osteoclasts
and osteoblasts would be promising for the bone remodeling
balance and be helpful for the development of therapeutic
agents.
Wedelolactone is a small molecular compound isolated from
Ecliptae herba. In China, Ecliptae herba is used as an herbal
kidney-nourishing drug and also is commonly believed to have
the ability to strengthen bones. It is also used to treat bone
diseases such as osteoporosis. Wedelolactone has been reported
to possess various biological activities, including inhibition of 5-
lipoxygenase and typsin, antagonizing myotoxins, and inducing
caspase-dependent apoptosis (Wagner and Fessler, 1986; Melo
and Ownby, 1999; Syed et al., 2003; Sarveswaran et al., 2012).
Recently, it was reported that Ecliptae herba extract showed a
therapeutic effect on bone metabolism of ovariectomized rats
(Zhang et al., 2013). We previously reported that wedelolactone,
as the major active constituent in Ecliptae herba, inhibited the
proliferation and differentiation of osteoclastic RAW264.7 and
mouse monocytes from blood (Liu et al., 2014).
In this study, we used wedelolactone-treated bone marrow
mesenchymal stem cell (BMSC)-derived conditioned medium to
treat osteoclastic RAW264.7 cells. The differentiation and bone
resorptive activity of RAW264.7 cells was evaluated. Interestingly,
compared to RANKL-treated alone, RAW264.7 cells exposed
to conditioned media for 4 days showed a significant decrease
in osteoclastic differentiation and function. The production of
Sema3A from BMSC was evaluated. The role of wedelolactone-
induced Sema3A/Plexin A1/NRP1 pathway in BMSC and in
osteoclastic RAW264.7 cells was then subsequently investigated.
MATERIALS AND METHODS
Isolation and Culture of Mouse Bone
Marrow Mesenchymal Stem Cells
(BMSCs)
BMSC were isolated according to a previously published protocol
with some modifications (Krebsbach et al., 1999; Zhang et al.,
2009). Briefly, BMSC were isolated from bone marrow, which
was aspirated from 8-week old BALB/c mice. All procedures
involving mice were carried out in compliance with the
relevant laws and institutional guidelines, and approved by
the Ethics Committee at Dalian Medical University. BMSC
were collected using gradient centrifugation of mesenchymal
stem cell-specific gradient solutions (Tianjin Haoyang Biological
Manufacture, China). A layer of the bone marrow cell fraction
in phosphate-buffered saline (PBS) was placed on top of
the gradient solution and centrifuged at 340 g for 20 min.
The cell fraction was collected and washed with PBS after
centrifugation. The cell samples were resuspended in Minimum
Essential Medium Alpha Medium (α-MEM, Gibco, Paisley,
UK), supplemented with 10% fetal calf serum (FCS), 100 U/ml
penicillin, and 100 µg/ml streptomycin, and maintained at
37◦C with 5% CO2 in a humidified atmosphere. On day
3, the cell suspension was replaced with fresh complete
medium. BMSC were further separated from hematopoietic
cells by their differential adhesion to tissue culture plastic and
prolonged proliferation potential. After 6–7 days in culture, 90%
confluence was reached. These cell samples were used in the
experiment.
Conditioned Media Preparation
BMSC were cultured with osteogenic medium (OS) (100 nM
dexamethasone, 1 mM β-glycerophosphate, and 5 µM L-ascorbic
acid 2-phosphate) + 2 µg/ml wedelolactone. Wedelolactone
was provided by Key Laboratory of Separation Science for
Analytical Chemistry at Dalian Institute of Chemical Physics,
Chinese Academy of Sciences (Dalian, China). The purity
was >98%. These cells were incubated for 12 days at 37◦C
with 5% CO2 in a humidified incubator. Every 3 days the
medium was changed and collected. The 3-, 6-, 9-, and 12-
day incubation fractions containing wedelolactone-treated or -
untreated conditioned media were harvested for use.
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Culture of Pre-osteoclastic RAW264.7
Cells
Mouse pre-osteoclastic RAW264.7 cells were purchased from
the Type Culture Collection of Chinese Academy of Sciences
(Shanghai, China). The cells were cultured in DMEM (Gibco,
Grand Island, NY, USA) supplemented with 10% FCS, 0.03%
L-glutamine (Gibco), penicillin (100 U/ml), and streptomycin
(100 µg/ml) and maintained at 37◦C with 5% CO2 in a
humidified atmosphere.
For differentiation, cells were plated in DMEM or conditioned
medium supplemented with 30 ng/ml recombinant RANKL. For
drug assays, wedelolactone was added to the culture medium
at different concentrations. Cells were incubated for 4 days at
37◦C with 5% CO2 in a humidified incubator and fed daily with
RANKL-supplemented medium.
MTT Assay
RAW264.7 cells were plated at a density of 1 × 104 cells
per well of 96-well plates. After overnight incubation, RANKL,
wedelolactone, or conditioned media was added to the plates.
Following incubation for 6 days, cell growth was measured
by 3-(4, 5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide
(MTT) with a plate reader (Tecan, Switzerland) as previously
described (Liu et al., 2014). The percentage of proliferation was
calculated with the formula:
Proliferation rate (%) = A492 (sample)/A492 (control) × 100%.
Measurement of TRAP Activity
RAW264.7 cells were fixed with 60% citrate buffered acetone for
30 s. The fixed cells were then washed with water 3× and were
further incubated with 100 µl phosphatase substrate solution
containing 10 mM pNPP and 10 mM sodium tartrate in 50 mM
citrate buffer (PH 4.6) at 37◦C for 1 h. After incubation,
the enzyme reaction mixture was transferred to another plate,
and the reaction was stopped with 100 µl of 0.1 N NaOH.
Absorbance at 405 nm was measured using an ELISA reader
(Tecan, Switzerland).
For staining of tartrate-resistant acid phosphatase (TRAP),
cells were fixed with 60% citrate buffered acetone for 30 s. The
cells were then stained for TRAP with 0.1 M acetate solution (PH
5.0) containing 6.76 mM sodium tartrate, 0.12 mg/ml naphthol
AS-MX phosphate, and 0.07 mg/ml of fast Garnet GBC solution
as described in the manufacturer’s instruction (Sigma, St. Louis,
MO, USA). Photomicrographs were obtained using an Olympus
microscope at 200×magnification.
ALP Activity Assay
For in vitro osteoblast differentiation, mouse BMSC were isolated
from 8-week old BALB/c mice according to a previously
published protocol, and were cultured with α-MEM with 10%
FBS. After 5 days, cells were reseeded (1 × 104 per cm2) and
cultured with OS. Culture medium was changed every third day.
After 9 days, alkaline phosphatase (ALP) staining (Sigma) and
activity measurements were performed by using an ALP staining
kit according to manufactory’s instruction.
Western Blot Analysis
For Western blot analysis, cells were lysed using lysis buffer
containing 10 mM Tris/HCl (PH 7.5), 150 mM NaCl, 2 mM
EDTA, 1% (v/v) Triton X-100, 1 mM Na3CO4, 1 mM PMSF, and
0.1 mM aprotinin. The cells were scraped from the plates and
centrifuged at 16,060 g for 30 min at 4◦C. For nuclear protein
extraction, the pellet from the 700 g centrifugation was washed
by buffer A, resuspended in buffer B containing 20 mM HEPES,
pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 10 mM
NaF, 2 mM Na3VO4, 1 mM pyrophosphoric acid, and Complete
TM protease inhibitors (Cell Signaling, USA) and incubated
on ice for 5 min. The protein concentration in the cell lysates
was determined using the Bradford protein assay. Western blot
analysis was performed as previously described using the several
antibodies (Bennett et al., 2005). Sema3A, plexin A1, and NRP1
antibodies were obtained from ABcam, Cambridge, UK. PLCγ2,
phospho-PLCγ2, β-cateinin, and DAP12 antibodies were from
Cell Signaling, USA.
Immunoprecipitation Assay
For immunoprecipitation assay, cells were harvested and lysed
in radioimmuno- precipitation assay (RIPA) buffer. Cell lysates
were then centrifuged at 12,000 rpm for 10 min at 4◦C (Hayashi
et al., 2012). PlexinA1 or IgG antibodies were added into
the supernatant and incubated at 4◦C overnight with rotation.
Protein A or G agarose beads (Thermo, Rockford, IL, USA)
were then added and incubated with rotation for 3 h at
4◦C. After centrifugation, proteins were subjected to Western
blotting.
Quantitative Real-Time RT-PCR
All work was carried out in a designated PCR-clean area.
RNA was extracted from cells using Trizol reagent (Gibco-
BRL, Rockville, MD, USA) and isolated as specified by the
manufacturer. The RNA was DNAse-treated (DNase I-RNase-
Free, Ambion) to remove any contaminating DNA; 200 ng
of total RNA was reverse-transcribed with oligodT primers
using the High Capacity cDNA RT Kit (Takara, Japan) in
a 20-µl cDNA reaction, as specified by the manufacturer.
For quantitative PCR, the template cDNA was added to a
20 µl reaction with SYBR GREEN PCR Master Mix (Applied
Biosystems) and 0.2 µM of primer. The amplification was carried
out using an ABI Prism 7000 for 40 cycles under the following
conditions: (1) an initial denaturation of 95◦C for 10 min plus
40 cycles of 95◦C for 15 s and (2) 60◦C for 1 min. The -fold
changes were calculated relative to β-actin (NM_007393.5)
using the 11Ct method for Sema3A (NM_001243073.1)
mRNA analysis. The following primer sets consisted of mouse
β-actin: forward, 5′-GTACGCCAACACAGTGCTG-3′; reverse,
5′-CGTCATACTCCTGCTTGCTG-3′ and mouse Sema3A:
forward, 5′-AGTGTCCGTACGATCCCAAG-3′; reverse,
5′-GAACAGTGACCACCGTCATC-3′.
Statistical Analysis
Differences between experimental groups were evaluated by
one-way analysis of variance (ANOVA) using SPSS 17.0
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software. Differences with a P-value < 0.05 were considered
statistically significant. All experimental data are presented
as the mean ± SEM with values from more than three
experiments.
RESULTS
Effect of Conditioned Media from
Wedelolactone-Treated BMSC on
Osteoclastic RAW264.7 Differentiation
To determine the influence of wedelolactone-treated conditioned
media from BMSC on osteoclastic differentiation, TRAP activity
of osteoclastic RAW264.7 cells was examined after treatment
with wedelolactone or conditioned media. As shown in Figure 1,
when RAW264.7 cells were exposed to RANKL for 4 days, TRAP
activity was significantly increased. After addition of different
conditioned media fractions, which were treated with 2 µg/ml
wedelolactone for 3, 6, 9, and 12 days, TRAP activity decreased
but to different levels. The decreased amount of TRAP activity
was most potent with the addition of the 9-day conditioned
medium fraction (Figure 1). The effects of wedelolactone and
9-day conditioned medium on RAW264.7 cell viability was
evaluated.
The 9-day conditioned medium fraction or wedelolactone
at 2 µg/ml did not influence cell viability in the MTT assay
(Figure 2A). However, TRAP staining confirmed that the
RANKL-induced increased number of TRAP-stained positive
RAW264.7 cells was significantly reduced by incubation with
2 µg/ml wedelolactone. In contrast, treatment with the 9-
day conditioned medium fraction led to a more significant
FIGURE 1 | Effect of wedelolactone-treated bone marrow
mesenchymal stem cell (BMSC) conditioned media on osteoclastic
differentiation of RAW264.7 cells. Different fractions of
wedelolactone-treated BMSC conditioned media were added to RAW264.7
cells. After 4 days of incubation, cultures were fixed, and TRAP activity was
assayed. Data are expressed as mean ± SEM of three independent
experiments. ∗P < 0.05 compared with RANKL-treated cells. #P < 0.05
compared with wedelolactone-treated cells.
FIGURE 2 | Effect of wedelolactone-treated BMSC conditioned media
on RAW264.7 cell proliferation and TRAP activity. (A) RAW264.7 cells
were treated with RANKL, wedelolactone or a 9-day conditioned medium
fraction for 4 days. An MTT assay was then performed; n = 3, mean ± SEM.
(B) RAW264.7 cells were incubated with the 9-day conditioned medium
fraction for 4 days. RAW264.7 cells were treated with conditions as follows:
(a) control; (b) RANKL; (c) RANKL+ wedelolactone; (d) RANKL+ conditioned
media for 9-day fraction. Cells were then stained for TRAP by using a TRAP
staining kit and imaged at 200×.
decrease in the number of TRAP-stained positive RAW264.7 cells
(Figure 2B).
Effect of Wedelolactone on the
Production of Sema3A from BMSC
Sema3A is reported to be produced from osteoblasts (Hayashi
et al., 2012). To examine whether wedelolactone stimulated the
production of Sema3A from BMSC, qRT-PCR assay was first
performed. It was observed that the Sema3A mRNA expression
level was upregulated after wedelolactone treatment of BMSC for
9 days (Figure 3). We added different concentrations of Sema3A
antibody to BMSC, and then the activity of ALP, a marker enzyme
for osteoblast differentiation, was determined. The increased
number of ALP staining-positive BMSC by wedelolactone was
reduced by addition of 0.5 or 1 µg/ml Sema3A antibody
(Figure 4A). Morphological changes further confirmed that
1 µg/ml Sema3A antibody blocked the increase in the number of
ALP-staining positive BMSC (Figure 4B). In addition, although
1 µg/ml Sema3A antibody did not affect the reduction in
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FIGURE 3 | Effect of wedelolactone on Sema3A mRNA expression in
BMSC. BMSC were incubated with OS medium containing wedelolactone for
9 days. Total RNA was then isolated. Gene expression was analyzed by
rt-qPCR with Sema3A specific primer sets. The expression levels were
normalized to the housekeeping genes Actb. Data are expressed as
mean ± SEM of three independent experiments. ∗P < 0.05 compared with
OS-treated control.
wedelolactone-induced TRAP activity in osteoclastic RAW264.7
cells, the decrease in TRAP activity caused by exposure to the
9-day conditioned medium fraction was reversed by Sema3A
antibody (Figure 4C). These results suggest that wedelolactone-
stimulated Sema3A production contributed to the enhancement
of ALP activity in BMSC and inhibition of TRAP activity in
RAW264.7 cells.
Wedelolactone Regulates
Osteoblastogenesis through
Sema3A/NRP1/PlexinA1
Pathway-Mediated β-Catenin Activation
The activity of Sema3A on osteoblasts is mediated by its
binding to the cell surface receptor consisting of Nrp1 and
plexinA1. To determine the mechanism by which wedelolactone
stimulated the production of Sema3A and subsequently
enhanced osteoblastogenesis, the binding of NRP1, plexin-A1,
and DAP12 was examined after treatment of BMSC with
wedelolactone. Wedelolactone treatment (2 µg/ml) enhanced the
binding of NRP1 and plexin-A1, while inhibition of Sema3A by
its antibody reduced the formation amount of NRP1-plexin-A1
complex. The formation of the Sema3A-plexin-A1 complex was
increased by wedelolactone, but the Sema3A antibody had no
effect on the increased amount of the wedelolactone-induced
Sema3A-plexin-A1 complex (Figure 5A).
The Sema3A signaling pathway is known to induce activation
of the Wnt/β-catenin signaling pathway, which is crucial for
osteoblast differentiation (Hens et al., 2005; Pederson et al., 2009).
Therefore, we focused on nuclear translocation of β-catenin, a
transcription factor involved in osteoblast differentiation. When
BMSC were treated with wedelolactone, an increase in nuclear
accumulation of β-catenin was observed. However, addition of
the Sema3A antibody reversed the enhanced wedelolactone-
induced nuclear translocation (Figure 5B). These results suggest
that wedelolactone promoted the formation of a Sema3A-NRP1-
plexin-A1 complex and subsequently activated β-catenin, which
resulted in BMSC differentiation toward osteoblasts.
Involvement of Plexin A1/Nrp1/DAP12
Pathway Activation during Inhibition of
Osteoclastogenesis by Wedelolactone
In contrast to osteoblasts, the activity of Sema3A on osteoclasts is
mediated through inhibition of RANKL-induced formation
of the plexinA1-DAP12 complex but without affecting
the plexinA1-Nrp1 complex. To examine the impact of
wedelolactone on the activation of the Sema3A signaling
pathway in osteoclasts, the expression of plexinA1 associated
with Nrp1 or DAP12 was determined. As shown in Figure 6A,
addition of RANKL to RAW264.7 cells induced the formation
of the plexinA1-DAP12 complex by sequestering plexinA1
from Nrp1, which was consistent with that of previously
reported results (Hayashi et al., 2012). The RANKL-induced
increase in the amount of DAP12 associated with plexinA1 was
downregulated by conditioned media, while the decrease in the
amount of Nrp1 associated with PlexinA1 was upregulated
by wedelolactone. Furthermore, incubation with the 9-
day conditioned medium fraction enhanced the effect of
wedelolactone on the plexinA1-NRP1 complex formation,
indicating that wedelolactone combined with Sema3A activated
the plexinA1-NRP1 pathway. Phospholipase C (PLC)γ2 acts
downstream of the plexinA1/NRP1/DAP12 pathway, which
participates in osteoclastogenesis. To determine whether
PLCγ2 activation was involved in wedelolactone-reduced
osteoclastogenesis, phosphorylation of PLCγ2 was monitored.
RANKL-induced phosphorylation of PLCγ2 was inhibited by
wedelolactone treatment. Addition of the 9-day conditioned
medium fraction resulted in a more significant decrease in
phosphorylation of PLCγ2 expression (Figure 6B), indicating
that wedelolactone activated the plexin A1//NRP1/DAP12
pathway and subsequently inhibited PLCγ2 activation, thus
leading to reduced osteoclastogenesis.
DISCUSSION
Bone homeostasis requires the coupling of bone resorption
and bone formation. An excess of osteoclastic bone resorption
over osteoblastic bone formation can result in bone-related
diseases such as osteoporosis. Osteoblasts and osteoclasts
are coupled by various coupling factors, which maintain
bone remodeling homeostasis. Some coupling factors such
as sclerostin, which is produced from osteoclastic precursors,
reduce bone formation. Some osteoclast-derived coupling factors
such as sphingosine 1-phosphate, however, induced osteoblast
differentiation (Goetzl et al., 2000). Interestingly, Sema3A,
as a dual function coupling factor, which is secreted by
osteoblastic cells, inhibits osteoclastic activity and at the same
time, promotes osteoblastic differentiation (Hayashi et al.,
2012). It appears to be useful for preventing bone loss.
Mice lacking Sema3A were found to have undergone bone
loss (Fukuda et al., 2013). Therefore, regulation of Sema3A
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FIGURE 4 | Effects of Sema3A antibody on wedelolactone-induced ALP activity in BMSC and TRAP activity in RAW264.7 cells. (A) BMSC were cultured
in OS medium containing 2 µg/ml wedelolactone and Sema3A antibody for 9 days. The cells were fixed and stained for ALP activity. The data represent the
mean ± SEM (n = 3). (B) ALP staining for BMSC. The cells were treated with conditions as follows: (a) control; (b) OS; (c) OS+wedelolactone; (d)
OS+wedelolactone + Sema3A antibody for 4 days. Cells were then stained for ALP by using a ALP staining kit and imaged at 200×. (C) TRAP activity in RAW264.7
cells were assayed after the cells were treated with conditioned media for 9-day fraction or Sema3A antibody for 4 days. The data represent the mean ± SEM
(n = 3). ∗P < 0.05 compared with RANKL-treated cells. #P < 0.05 compared with conditioned media-treated cells.
and its corresponding signaling pathway may be helpful for
treatment of osteoporosis (Behar et al., 1996). In cultured
chick dorsal root ganglion neurons, several small molecular
drugs have been reported to interfere with Sema3A activity
through inhibition of Sema3A-induced growth cone collapse
(Kikuchi et al., 2003; Kaneko et al., 2006). However, it has
not been shown that small molecular compounds stimulate
Sema3A activity to prevent of bone loss. In this study,
wedelolactone, a compound isolated from Ecliptae herba,
stimulated Sema3A mRNA expression, indicating that the
wedelolactone’s mechanism of action appeared to be promotion
of Sema3A activity, distinct from the known Sema3A activity
inhibitor.
Wedelolactone is a component isolated from Ecliptae herba,
which is widely used in China to strengthen bones. Our previous
study showed that wedelolactone inhibited RANKL-induced
osteoclast differentiation (Liu et al., 2014). In this study, we
further investigated the role of wedelolactone in the coupling of
osteoclast and osteoblasts during earlier precursor stages. Mature
osteoblastic cells are derived from BMSC, which secret various
factors, including Wnt and BMP, to induce differentiation toward
osteoblasts (Jaiswal et al., 1997; Hens et al., 2005). Upon 9 days
of treatment with wedelolactone, the mRNA expression levels of
Sema3A increased. A 9-day conditioned medium fraction was
further confirmed to contain biologically active Sema3A protein,
as confirmed by inhibition of ALP activity by Sema3A antibody.
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FIGURE 5 | Effect of wedelolactone on the formation of Sema3A/NRP1/PlexinA1 complex and nuclear accumulation of β-catenin in BMSC. BMSC
were seeded in 10-cm plate and treated with or without 2 µg/ml wedelolactone for 9 days. The cells were lysed and subjected to coimmunoprecipitation assays
(A) or Western blot assays (B). Data are expressed as mean ± SEM of three independent experiments. ∗P < 0.05 compared with OS-treated control. #P < 0.05
compared with wedelolactone-treated cells.
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FIGURE 6 | Effect of wedelolactone on the formation of NRP1-PlexinA1 and PlexinA1-DAP12 complex, and PLCγ2 activation in RAW264.7 cells.
RAW264.7 cells were treated with RANKL for 4 days in the presence of OS, wedelolactone, BMSC conditioned media (CM1) and wedelolactone-treated conditioned
media for 9-day fraction (CM2). Then the cells were lysed and subjected to coimmunoprecipitation assays (A) or Western blot assays (B). The data represent the
mean ± SEM (n = 3). ∗P < 0.05 compared with untreated control. #P < 0.05 compared with RANKL+OS group.
However, fractions obtained from more or less than 9 days of
incubation (such as 6 or 12 days) had no obvious inhibitory effect
on TRAP activity of RAW264.7 cells, suggesting that Sema3A
derived from BMSC was induced by wedelolactone at the 9-day
differentiation stage. These results were similar to those from a
previous study of upregulated Sema3A mRNA expression from
calvarial cells stimulated by 1α, 25 (OH)2D3 and PGE2 (Hayashi
et al., 2012).
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In osteoblasts, Sema3A was shown to associate with plexin
A1 and Nrp1, which induces the downstream activation of the
Wnt pathway (Narazaki and Tosato, 2006). Sema3A production
from wedelolactone-stimulated BMSC resulted in the formation
of the plexin A1-Nrp1 and plexin A1-Sema3A complexes,
indicating that wedelolactone-induced osteoblast differentiation
was mediated through the Sema3A/Plexin A1/Nrp1 pathway.
Blockage of active Sema3A by addition of Sema3A antibody
reversed the increase in the amount of the plexin A1-Nrp1
complex but had no effect on the amount of the plexin A1-
Sema3A complex, indicating that addition of Sema3A antibody
was not enough to block the binding of plexin A1 with Sema3A;
wedelolactone, however, was able to promote the formation
of the plexin A1-Sema3A and plexin A1-Nrp1 complexes.
β-Catenin has been shown to be a key transcription factor
of Wnt pathway, which is responsible for osteoblastogenesis
(Day et al., 2005). A previous study reported that Wnt3a-
induced nuclear accumulation of β-catenin was suppressed in
Sema3A−/− calvarial cells (Hayashi et al., 2012). In this study,
wedelolactone treatment resulted in the nuclear accumulation
of β-catenin. However, neutralization of Sema3A by addition of
the Sema3A antibody partially inhibited nuclear accumulation
of β-catenin, indicating that wedelolactone-stimulated β-catenin
activation through nuclear translocation acted downstream of the
plexin A1-Nrp1 complex.
In osteoclasts, RANKL has been reported to downregulate
Nrp1 expression, resulting in osteoclast differentiation via
sequestration of plexin A1 from Nrp1 with formation of
plexin A1-DAP12 complex (Takahashi and Strittmatter, 2001;
Takegahara et al., 2006). In this study, the RANKL-induced
formation of the plexin A1-DAP12 complex in osteoclastic
RAW264.7 cells was inhibited by conditioned media and
wedelolactone, while the amount of plexin A1 associated
with Nrp1 increased. This result was consistent with the
previous study that reported Sema3A binding to the plexin
A1-Nrp1 complex followed by suppression of RANKL-induced
osteoclast differentiation via a reduction in the formation of
the plexin A1-DAP12 complex (Hayashi et al., 2012). Addition
of Sema3A antibody reversed the effects of conditioned media
on the formation of the plexin A1-Nrp1 complex and PLCγ2
activation, since PLCγ2 phosphorylation was indicated to be
related to Sema3A signaling (Mao et al., 2006; Epple et al.,
2008; Faccio and Cremasco, 2010). In the current study, in
addition to the role of Sema3A in the conditioned media,
wedelolactone was also implicated in direct mediation of
the Sema3A/plexin A1/Nrp1 pathway instead of the plexin
A1/DAP12 pathway. However, we do not know whether the
action of wedelolactone did or did not directly interfere
with the interaction of the Sema3A/plexin A1/Nrp1 pathway.
Additional studies concerning the target for wedelolactone
on osteoblasts and osteoclasts are needed. A previous study
showed that wedelolactone inhibited breast cancer-induced
osteoclastogenesis through inhibition of IκBα phosphoration
(Hsieh et al., 2015). NF-κB pathway acts downstream of
Sema3A signaling. The upregulated expression of Nrp1 by
wedelolactone might be attributed to inhibition of the NF-κB
pathway.
Of note, quite a few studies indicate that plexins and
semphorins family proteins have multiple roles. Genetic as
well as pharmacological in vivo experiments have indicated
that therapeutic interventions with Sema3A may also cause
adverse effects (Goshima et al., 2012). Wedelolactone is suggested
to regulate osteoblasts and osteoclasts by stimulating Sema3A
activity. Concurrently, wedelolactone was able to alter other
pathways such as the NF-κB pathway. This multi-target effect of
wedelolactone might prevent the side effects of Sema3A.
CONCLUSION
In the present study, we demonstrated that effective stimulation
of Sema3A production from BMSC by wedelolactone contributed
to osteogenesis. Wedelolactone and wedelolactone-treated 9-day
conditioned medium fraction from BMSC exerted inhibitory
effects on osteoclastogenesis via Sema3A/plexin A1/Nrp1
signaling.
In BMSC, wedelolactone induced the binding of plexin
A1/Nrp1 and activated downstream molecules of Wnt/β-catenin
pathway.
In osteoclastic RAW264.7 cells, the plexin A1-DAP12 complex
was sequestered by wedelolactone with subsequent inhibition of
PLCγ2 phosphorylation.
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